Acutaas Chemicals Ltd — Q4 FY26
Acutaas Chemicals delivered a stellar Q4 FY26 with revenue of 432.8 cr (+40.3% YoY) and EBITDA of 183.5 cr (margin 42.4%, +1487 bps YoY), driven by strong CDMO ramp-up, portfoli...
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
67%Questions answered3Evaded / deflected12Questions auditedContradictedNumbers vs filing
Answered
Medium priority
Expansion on R&D center and its purpose.
Asked by Ricken Sha, Boring AMC
Management explained the purpose and need for the new R&D center.
Read the exchange
Question
just like uh first uh a little bit if you all can expand on the R&D center that you all mentioned and you know what is the idea behind that going ahead.
Naresh (likely CEO)
the R&D center which we are doing is for upgrading and enhancing our capability and capacity with our existing R&D center because our existing center is having uh uh capacity which can cater uh all the requirement but we are expecting lot more inquiries and more uh traction towards the new molecule.
Partial answer
High priority
Growth plans for base business (advanced intermediates) excluding CDMO.
Asked by Ricken Sha, Boring AMC
Management discussed margin improvement but did not quantify revenue growth for base business.
no specific growth rate givenfocused on margin rather than revenue growth
Read the exchange
Question
what is the base business looking like today and do we have any growth plans for the same for the next uh two financial years?
Naresh (likely CEO)
we had some portfolio reshuffleling for our pharma intermediate business X of CDMO and that has yielded us in terms of margin expansion. I have already mentioned during my commentary that after 9 months of FI 20 uh 6, it has gone sequentially in Q4 FI26 and expected to go grow further in FI27 as well.
Evasive
High priority
Meaningful contribution from battery chemicals in FY27.
Asked by Ricken Sha, Boring AMC
Management confirmed contribution but refused to quantify, using 'meaningful' without specifics.
no number givenvague 'meaningful'
Read the exchange
Question
in FY27 does this seem like a decent contribution?
Naresh (likely CEO)
Definitely in FY27 it will have a meaningful uh revenue contribution. It will start slowly with the Q1 and till Q4 it will keep on ramping up and at the end of complete financial year FYI 27 we will definitely have a meaningful uh revenue contribution. I will not put it any number to it as of now because there are many variables but uh it will be a meaningful contribution.
Partial answer
Medium priority
Contribution from new electrolyte products in FY27.
Asked by Ricken Sha, Boring AMC
Management described timeline but did not quantify contribution.
no revenue or volume numbers
Read the exchange
Question
are we taking any sort of uh contribution from the uh two new electrolytes we have added or this is just the you know two products we have discussed before.
Naresh (likely CEO)
the capex is already going on for the third uh uh electrolyte additive product and which is getting completed by uh Q2 uh Q1 FI27. So once that gets completed it will also start contributing in the revenue and the fourth uh uh product we are in the phase of business development.
Evasive
High priority
Contribution from four new CDMO products in FY27.
Asked by Ricken Sha, Boring AMC
Management confirmed contribution but gave no quantification.
no revenue numbersvague 'good revenue expectation'
Read the exchange
Question
for FI27 do these four to five products also contribute something.
Naresh (likely CEO)
Yes definitely as you mentioned those are all validated product and we are uh building it as good revenue expectation from these four products as well apart from the first product.
Answered
High priority
Reason for goodwill increase and recoverability confidence.
Asked by Govid Goyel, Siri Nerfa
Management explained the accounting rationale and expressed confidence in recoverability.
Read the exchange
Question
can you please elaborate on uh this increase in the goodwill happened in a 26 over 25 specifically uh if this pertains to the indic which is which is a newly incorporated entity. uh I would like to understand uh what is the rational for uh goodwill at this stage and and further uh can you also clar give some clarity on on on the basis for which the management is showing the confidence on the on the recoverability of this total goodwill of 104 CR
Bas (CFO) and Naresh
when we have made an uh investment of 190 cr uh in indicam so the partner has bring in the capital that was at par value only so for 25% which is uh there for our partner so whatever we have paid 190 cr out of that 25% uh is going towards the uh goodwill in our books of account. ... we are very much confident that uh this business in coming years is going to do excellently well.
Answered
Medium priority
Background of JV partner and expertise brought.
Asked by Govid Goyel, Siri Nerfa
Management provided background on partner's experience and team.
Read the exchange
Question
what is the background of uh uh of that partner like what kind of expertise they are bringing in because uh this JV is not having any revenue so far.
Naresh (likely CEO)
our partner he has been working in this uh space for more than uh 30 years and uh he uh so he is a veteran in this business understand the Korean ecosystem well apart from the uh international customer outside Korea like Taiwan and Japan and he has assembled a good team of people coming from the production and R&D and regulator regulatory side.
Answered
High priority
Developments on new CDMO products and potential opportunity size.
Asked by Sanil Jan, Ambbit Capital
Management gave a range for peak revenue potential per product.
Read the exchange
Question
can you give us some developments on the new CDMO products under progress other than the FM formium contract and what can be the potential opportunity size of it.
Naresh (likely CEO)
we have a long pipeline of uh CDMO products but we have announced validation of four more products after the first one ... in terms of revenue potential we are expecting those product to be uh between 50 200 cr each at a peak level
Answered
High priority
EBITDA margin for specialty chemicals and advanced intermediates separately.
Asked by Sanil Jan, Ambbit Capital
Management provided specific margin percentages for each segment.
Read the exchange
Question
we have reported excellent aida margins of 42%. So can you tell us what was the margin for speciality chemicals and inter advanced intermediates separately?
Bas (CFO)
for our pharma business uh uh for this quarter uh a bit margin is around 44% and for speciality it is around 13%. ... for pharma it is 44% and for speciality it is 29%
Evasive
High priority
Revenue potential from semiconductor and battery chemicals over 3-5 years.
Asked by Nikon Gupta, AK investment
Management gave capacity but no revenue or margin projections.
no revenue numbersno margin guidancedeferred to capacity
Read the exchange
Question
what is the revenue potential from the semiconductor chemicals and battery chemicals business over the next 3 to 5 years? And also if you can put some light on Eida margins as well that would be very helpful.
Naresh (likely CEO)
for electrolyte additive business it's a function of capacity what we have built in and as of now the capacity for electrolyte additive is 2,000 mington for VC and APC. So based on that you can see the revenue potential coming in from that business and related to semiconductor business that business has been going through some difficult phase in last financial year but now it has recovered from Q4 onwards
Answered
High priority
Expected EBITDA margin range for FY27.
Asked by Saiikumar, family fund
Management gave a clear expectation of similar margin range.
Read the exchange
Question
this year you have consolidated it yearly margins around 34.5%. Somewhere around 35. So for the FI27 what kind of range you are expecting?
Bas (CFO)
we are expecting similar kind of margin in FI27 also for us the margin is a function of product mix and we expect similar kind of product mix in FI27 that's the reason we see that it should be in a similar range only
Answered
Medium priority
Capacity utilization for plants in Q4.
Asked by Jason Son, IDBI Capital
Management provided specific utilization percentages.
Read the exchange
Question
just wanted to know the capacity utilization for the suchin plant the jagardia plant and the glacial facility for this quarter under review
Bas (CFO)
utilization at suchin plant is 75%. Unit 2ar is 31%. And unit 3 jagadia is 50%.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Pharma EBITDA margin 44%, Specialty 29% in Q4 | 44% | 42.4% | Overstated vs filing |
| Specialty EBITDA margin 29% in Q4 | 29% | 42.4% | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.